We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+9.25%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$398M
AUM Growth
+$20.8M
Cap. Flow
+$11.1M
Cap. Flow %
2.8%
Top 10 Hldgs %
51.36%
Holding
92
New
12
Increased
23
Reduced
18
Closed
5

Top Buys

Rank Stock Value
1
CBAY
Cymabay Therapeutics
CBAY
+$4.8M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$3.99M
3
AXGN icon
Axogen
AXGN
+$3.98M
4
ACET icon
Adicet Bio
ACET
+$3.83M
5
BMEA icon
Biomea Fusion
BMEA
+$3.32M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$11.8M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$3.81M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$2.74M
4
AFMD
Affimed
AFMD
+$2.43M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$1.83M

Sector Composition

Rank Sector Weight
1 Healthcare 94.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OTIC
26
DELISTED
Otonomy, Inc.
OTIC
$4.58M 1.15%
2,200,297
-179,095
-8% -$368K
NTUS
27
DELISTED
Natus Medical Inc
NTUS
$4.52M 1.14%
190,635
+94,982
+99% +$2.34M
ARAY icon
28
Accuray
ARAY
$33.2M
$4.49M 1.13%
941,800
– –
PRDS
29
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$3.82M 0.96%
233,500
-66,450
-22% -$773K
FSTX
30
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$3.48M 0.88%
693,785
– –
ALEC icon
31
Alector
ALEC
$165M
$3.21M 0.81%
155,247
+47,835
+45% +$1.08M
AFMD
32
DELISTED
Affimed
AFMD
$3.15M 0.79%
57,128
-39,358
-41% -$2.43M
AXGN icon
33
Axogen
AXGN
$2.43B
$3.11M 0.78%
+332,103
New +$3.98M
KALV
34
DELISTED
KalVista Pharmaceuticals
KALV
$2.52M 0.63%
190,663
+1,500
+0.8% +$23.9K
ITOS
35
DELISTED
iTeos Therapeutics
ITOS
$2.52M 0.63%
54,090
-28,971
-35% -$964K
LKFT
36
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
$2.35M 0.59%
42,675
-35,000
-45% -$1.83M
BMEA icon
37
Biomea Fusion
BMEA
$90.4M
$2.34M 0.59%
+313,923
New +$3.32M
RIGL icon
38
Rigel Pharmaceuticals
RIGL
$749M
$2.33M 0.59%
87,900
+7,000
+9% +$211K
TPTX
39
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$2.22M 0.56%
46,452
+4,500
+11% +$201K
LONA
40
LeonaBio Inc
LONA
$72.6M
$2.1M 0.53%
16,098
– –
VKTX icon
41
Viking Therapeutics
VKTX
$3.91B
$2.06M 0.52%
447,400
– –
AERI
42
DELISTED
Aerie Pharmaceuticals
AERI
$2.03M 0.51%
289,040
– –
COGT icon
43
Cogent Biosciences
COGT
$7.23B
$1.92M 0.48%
223,554
– –
ETNB
44
DELISTED
89bio
ETNB
$1.89M 0.48%
144,653
+18,001
+14% +$285K
KNTE
45
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$1.89M 0.47%
106,453
– –
MREO
46
Mereo BioPharma
MREO
$48.5M
$1.8M 0.45%
1,126,613
– –
RGLS
47
DELISTED
Regulus Therapeutics
RGLS
$1.75M 0.44%
+555,556
New +$2.47M
VERO
48
DELISTED
Venus Concept
VERO
$1.66M 0.42%
5,913
-834
-12% -$241K
IPSC icon
49
Century Therapeutics
IPSC
$353M
$1.59M 0.4%
100,135
+20,135
+25% +$378K
KURA icon
50
Kura Oncology
KURA
$818M
$1.55M 0.39%
110,829
+10,000
+10% +$162K
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return

DAFNA Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, DAFNA Capital Management held 92 positions worth $398M, up 5.5% from $377M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

DAFNA Capital Management's Q4 2021 filing shows 12 new, 23 increased, 18 reduced and 5 closed positions. Its largest new stake was Axogen: 332,103 shares worth $3.11M. The largest sale was Dicerna Pharmaceuticals, Inc., an estimated $11.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 91% a quarter earlier.

  • DAFNA Capital Management's largest Q4 2021 buy was Axogen: 332,103 shares worth $3.11M.
  • DAFNA Capital Management added most to Cymabay Therapeutics in Q4 2021, an estimated $4.8M increase.
  • DAFNA Capital Management's biggest Q4 2021 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $3.81M.
  • DAFNA Capital Management fully exited Dicerna Pharmaceuticals, Inc. in Q4 2021, selling an estimated $11.8M.
  • DAFNA Capital Management's ten largest holdings make up 51% of its $398M portfolio in Q4 2021.
  • DAFNA Capital Management opened 12 new positions and closed 5 in Q4 2021.
  • DAFNA Capital Management's portfolio value rose 5.5% quarter-over-quarter to $398M.

Based on DAFNA Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.